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Abstract
Background: Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease caused by deficient tissue-nonspecific isoenzyme of alkaline phosphatase activity that manifests as a broad range of signs/symptoms, including
bone mineralization defects and systemic complications. The burden of disease is poorly characterized, particularly
in children. This study aimed to characterize the patient-reported burden of disease among children with HPP using
two survey instruments: the HPP Impact Patient Survey (HIPS) and the HPP Outcomes Study Telephone interview
(HOST).
Methods: Between September 2009 and June 2011, pediatric patients (aged younger than 18 years) with HPP were
recruited to participate in the study via patient advocacy groups or their medical provider. Survey questions were
used to capture information on patient demographics, HPP-related medical history, mobility, and health-related
quality of life (HRQoL; using the 10-item Short-Form Health Survey for Children [SF-10], HIPS only).
Results: Common clinical features of the 59 pediatric survey respondents (mean [standard deviation] age: 7.6 [5.1]
years; 51% male) included pain (86% of patients), muscle weakness (71%), difficulty gaining weight (64%), and
delayed walking (59%). Fracture was reported by 36% of patients; multiple fractures were also reported (15% of
patients). Use of assistive devices for mobility was frequent among the study population (51%). In response to the
SF-10, patients reported a substantial impact of HPP on their HRQoL; physical function was the most severely
impaired component relative to normative data. Of patients responding to the HOST, two-thirds experienced
worsening of at least one of their HPP-related signs/symptoms over a 5-year period.
Conclusions: In pediatric patients, HPP is associated with a high burden of disease and a substantial negative
impact on HRQoL. The burden of HPP may increase and HRQoL reduce further over time as signs/symptoms that
affect HRQoL worsen or new signs/symptoms manifest.
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Background
Hypophosphatasia (HPP) is a rare, inherited, metabolic
bone disease caused by deficiency of the tissue non-specific isoenzyme of alkaline phosphatase (TNSALP) [1].
Low TNSALP activity leads to the extracellular
accumulation of its substrates including one of the key
substrates involved in the pathogenesis of HPP, inorganic pyrophosphate (PPi). PPi is a potent inhibitor of
bone mineralization [2]; in HPP, excess PPi contributes
to skeletal hypomineralization, which can result in the
premature loss of deciduous teeth, HPP-related rickets
in infants and children, and osteomalacia in patients of
any age [3].
HPP-related manifestations vary considerably between
individuals and, aside from skeletal and dental manifestations, can include systemic complications such as respiratory difficulties, vitamin B6-dependent seizures,
muscle weakness, nephrocalcinosis, and chronic pain
[4–6]. Mortality is high among those who present with
HPP in the perinatal and infantile periods [1]; however,
it is now recognized that significant complications
associated with HPP can occur at any age, and that those
individuals who survive infancy or who present with
HPP-related manifestations after infancy often experience a high disease burden [7]. These manifestations of
HPP are often debilitating and frequently include poor
growth [7–10], delayed motor milestones [9, 11], muscle
weakness [7, 10], gait abnormalities, chronic bone,
muscle and/or joint pain [12, 13], dental abnormalities
[14], and recurrent low trauma fractures [7, 15]. As the
disease progresses, these manifestations often lead to
ambulatory difficulties and limitations in activities of
daily living, which may result in individuals requiring
assistance with daily tasks. Consequently, individuals
with HPP frequently experience a diminished health-related quality of life (HRQoL) [7].
Several observational studies of pediatric patients
with HPP have reported the clinical burden of the
disease along specific parameters [1, 6, 10]. The
results of these studies suggest that patients often
experience a high burden of disease. Moreover, there
are publications based on data from case reports
reporting the loss of mobility over time in adults with
HPP, suggesting that many patients experience a
progressive worsening of the disease [16–18]. However, limited evidence on the patient-reported burden
of HPP and its impact on an individual’s HRQoL
exists in the literature, and to the best of our knowledge, research published to date has focused on patient-reported disease burden in adults with HPP, but
not children with the disease.
The aim of the current study was to evaluate and
characterize the patient-reported burden of disease in
pediatric patients with HPP.
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Methods
This was a cross-sectional, survey-based study of adult
and pediatric patients with HPP. Details of the materials
and methods as well as the results for the adult population have been published previously [7]. This paper
describes the results for the pediatric population (those
younger than 18 years of age at the time the survey was
administered). This paper was prepared according to the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) reporting guidelines for observational studies (Additional file 1) [19].
Survey instruments

Two complementary survey instruments, developed by
the study sponsor (Alexion Pharmaceuticals, Inc.,
Boston, MA, USA), were used to capture the patient-reported burden of HPP: the HPP Impact Patient Survey
(HIPS) and the HPP Outcomes Study Telephone interview (HOST) [7]. The HIPS survey is presented in
Additional file 2; the HOST survey has been published
previously [7]. The survey questions included in the
HIPS and HOST capture patient demographics, HPP-related medical history and symptoms, mobility, and
HRQoL. In addition, questions included in the HOST
capture change in symptoms over time. HRQoL was
assessed using the validated 10-item Short-Form Health
Survey for Children (SF-10), which was included as part
of the HIPS (Additional file 2, questions 1–7). For
questions relating to the timing of signs/symptoms, both
survey instruments captured data for the following age
groups: age 0 to less than 10 years, age 10 to less than
18 years, and age 18 years or older, while the HOST also
captured data for age 0 to less than 1 year).
Participants and survey administration

The HIPS was a web-based survey completed by the patients or their caregivers between September 9, 2009 and
June 15, 2011. The HOST was conducted predominantly
via telephone by six licensed physical therapists between
December 10, 2010 and March 12, 2011. There was no
specific rationale for surveying patients with the HIPS or
HOST. For both surveys, patients with HPP were invited
to participate via outreach from patient advocacy groups.
For the HOST, some patients were also invited by their
medical provider. All patients or their primary caregivers
provided informed consent prior to their participation in
the study. Participation did not require third-party
confirmation of HPP diagnosis. All survey responses
were anonymous.
Survey data analysis

Data from both surveys were combined for analysis
where possible. Data from questions unique to only one
of the survey instruments were analyzed separately. For
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the HOST, participants who did not respond to a
specific question were censored and omitted from the
analyses for that question. For data from the HIPS, if it
was not possible to differentiate a response of “no” from
a non-response, the response was conservatively classified as “no”.
Descriptive statistics were generated for all survey
participants; in all cases, the denominator was the number of responders for a given question. The difference
between reported age at first manifestation of HPP and
age at the time the survey instruments were administered was used to determine the length of time the
patient had been living with symptoms of HPP. Means
are reported as mean (standard deviation [SD]).
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Table 1 Patient demographics and characteristics of survey
respondents
Characteristic

Patients (n = 59)

Sex, n (%)
Male

30 (50.8)

Female

29 (49.2)

Mean height, cm (SD)
Male (n = 26)

106.5 (29.4)

Female (n = 27)

105.7 (35.1)
a

Mean height Z-score, (SD)
Male (n = 30)

−3.0 (3.5)

Female (n = 29)

−3.2 (2.3)

Age at survey, years

SF-10 scoring

Mean (SD)

7.6 (5.1)

Mean Physical Component Summary (PCS) and Mental
Component Summary (MCS) scores were calculated
from participant responses to the SF-10 included in the
HIPS. The scores were compared with the general child
population norm (mean: 50, SD: 10), which was based
on a US general population sample from 1998 [20].
Means and 95% confidence intervals (CIs) were calculated for summary and individual domain scores.

Range

0–17

Age at HPP symptom onset, years
Mean (SD)

0.8 (0.9)

Range

0–4

Duration of symptomatic disease, years
Mean (SD)

7.0 (5.0)

Range

0–16

a

Results
Study population

The HIPS and HOST were completed by a total of 184
respondents from 16 countries. Of these, 125 respondents were adults at the time of their participation in the
survey; data from these individuals have been published
[7]. The remaining 59 patients were less than 18 years of
age at the time of the survey and constitute the study
population (HIPS, n = 44; HOST, n = 15).
Of the pediatric survey respondents, 23.7% were
patients who self-completed the survey, and 74.6%
responded via their caregiver. One respondent (1.7%)
completed the survey on behalf of a patient but did not
identify themselves as either a caregiver or family
member. Patient demographics and characteristics of the
respondents are presented in Table 1. At the time of the
survey, the mean (SD) patient age was 7.6 (5.1) years,
and the mean (SD) reported age at onset of first HPP
signs/symptoms was 0.8 (0.9) years. Both sexes were
represented equally among the respondents (male, 51%;
female, 49%). The mean (SD) time from the first HPP
sign/symptom to participation in the study was 7.0 (5.0)
years, and the mean (SD) time from the first HPP sign/
symptom to diagnosis (captured in the HOST only) was
1.3 (2.3) years.
Occurrence of HPP-related signs/symptoms

Participants who responded to the HOST were asked to
identify their first HPP signs/symptoms (Table 2), as well

Mean height Z-scores were calculated using the Centers for Disease Control
and Prevention method; because the date of birth or exact age in months for
each patient was unknown, reported ages in whole numbers were rounded to
0.5 years (e.g. ages of 2 to < 3 years were rounded to 2.5 years)
HPP hypophosphatasia, SD standard deviation

as those that manifested later that were present at the
time of the survey. Signs/symptoms that manifested after
the respondents’ first HPP signs/symptoms are reported
here as ‘additional symptoms’. Dental problems were the
most commonly reported first HPP signs/symptoms
(46.7% of patients); respondents also reported first HPP
signs/symptoms of impaired mobility (40.0%), skeletal
abnormalities (33.3%), pain (26.7%), and other HPP
signs/symptoms (53.3%; other HPP signs/symptoms
included failure to thrive, vomiting, lack of appetite,
seizures, bulging fontanel, difficulty in gaining weight,
hypercalcemia, hypercalciuria, muscle weakness and respiratory difficulties) (Table 2). It is of interest that none
of the respondents reported fracture as a first HPP sign/
symptom. The following additional symptoms were reported to be present at the time of the survey: impaired
mobility (46.7% of patients), skeletal abnormalities
(40.0%), pain (40.0%), dental problems (20.0%), fractures
(6.7%), and other HPP signs/symptoms (53.3%; other
HPP signs/symptoms included recurrent respiratory
tract infections, nephrocalcinosis, lack of appetite, difficulty in gaining weight, tight hamstrings/calves, short
stature, growth disorders, low red blood cell count and
other dental/oral problems [abocclusion, malposition of
teeth, dysfunction of the tongue]).

Rush et al. Orphanet Journal of Rare Diseases

(2019) 14:201

Table 2 First and additional signs/symptoms experienced by
pediatric patients with HPP
Sign/symptom

Patients, n (%) (n = 15)

First sign/symptom
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Table 3 History of manifestations of HPP in pediatric patients
Manifestation

Patients, n (%)

Pain (any HPP-related pain)

51/ 59 (86.4)

Joint paina

27/44 (61.4)

a

Dental/tooth loss

7 (46.7)

Bone pain

23/44 (52.3)

Impaired mobility

6 (40.0)

Muscle paina

9/44 (20.5)

Skeletal abnormalities

5 (33.3)

Pain

4 (26.7)

Fracture

0 (0.0)

Other first sign/symptoma

8 (53.3)

Additional sign/symptom

Joint and muscle manifestations
Muscle weakness

41/58 (70.7)

Extremely flexible joints

21/57 (36.8)

Developmental manifestations
Difficulty gaining weight

38/59 (64.4)

Impaired mobility

7 (46.7)

Delayed walking

34/58 (58.6)

Skeletal abnormalities

6 (40.0)

Short stature

28/58 (48.3)

Pain

6 (40.0)

Seizuresa

4/44 (9.1)

Dental problems

3 (20.0)

Fractures

1 (6.7)

Bowing of legs or knock knees

Other additional sign/symptomb

8 (53.3)

Abnormally shaped chest

32/59 (54.2)

Abnormally shaped head

30/57 (52.6)

Knock knees

23/59 (39.0)

Bowing of legs

22/59 (37.3)

Bowing of arms

12/59 (20.3)

Data presented were assessed by HOST only. Respondents could report up to
three first signs/symptoms and up to three additional signs/symptoms
a
Other first signs/symptoms included failure to thrive, vomiting, lack of
appetite, seizures, bulging fontanel, difficulty in gaining weight, hypercalcemia,
hypercalciuria, muscle weakness, and respiratory difficulties. bOther additional
signs/symptoms included recurrent respiratory tract infections, nephrocalcinosis,
lack of appetite, difficulty in gaining weight, tight hamstrings/calves, short
stature, growth disorders, low red blood cell count, and other dental/oral
problems (abocclusion, malposition of teeth, dysfunction of the tongue)
HOST Hypophosphatasia Outcomes Study Telephone interview,
HPP hypophosphatasia

Burden of disease: general
Pain

HPP-related pain was frequently reported by the respondents (86.4%) (Table 3), and 71.2% of the respondents
reported that they had recently experienced pain (within
2–4 weeks). Of those who completed the HIPS, more
than half (52.3%) reported experiencing bone pain,
43.2% reported bone pain severe enough to limit their
activities, and 36.4% required medication for bone pain.
Systemic manifestations of HPP

The most frequently reported systemic manifestations of
HPP (excluding HPP-related pain) were muscle weakness (70.7% of patients), difficulty gaining weight
(64.4%), and delayed walking (58.6%) (Table 3). The occurrence of seizure in the patients’ medical histories
(assessed in the HIPS only) was the least frequently
reported symptom (9.1%). Overall, 25.0% of respondents
who completed the HIPS (n = 11/44) reported having
trouble breathing.
Burden of disease: skeletal
Skeletal abnormalities

The most frequently reported skeletal abnormalities
were bowing of the legs or knock knees (57.6% of patients), abnormally shaped chest (54.2%), and abnormally

Skeletal abnormalities
34/59 (57.6)

Respiratory manifestations
Pneumonia

16/59 (27.1)

Difficulty breathinga

11/44 (25.0)

Fractures
Non-vertebral fracturea
a

6/44 (13.6)

Pseudofracture

3/44 (6.8)

Non-healing fracturea

1/44 (2.3)

Data are expressed as the number of patients who reported a particular HPP
manifestation divided by the total number of patients who responded to the
question. All manifestations are captured by both the HIPS and HOST unless
stated otherwise. Bold italicized numbers indicate the three most
frequent symptoms
a
Assessed by HIPS only (n = 44)
HIPS Hypophosphatasia Impact Patient Survey, HOST Hypophosphatasia
Outcomes Study Telephone interview, HPP hypophosphatasia

shaped head (52.6%) (Table 3). Bowing of the arms was
the least frequently reported skeletal abnormality involving long bones (20.3%).
Fractures

A total of 35.6% (n = 21/59) of patients had experienced
at least one fracture (Fig. 1). Multiple fractures were also
reported: 15.3% of patients reported two or more fractures, which includes 5.1% of patients who reported six
or more fractures. Of respondents reporting at least one
fracture, the mean (SD; range) number of fractures was
2.4 (2.2; 1–8). The types of fracture were assessed by the
HIPS; non-vertebral fractures were the most commonly
reported (13.6% of patients), followed by pseudofractures
(6.8%) and non-healing fractures (2.3%) (Table 3).
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Burden of disease: function
Mobility

Fig. 1 Total fractures experienced by pediatric patients with HPP
(n = 59). There were seven respondents who did not respond to this
question in the survey. HPP, hypophosphatasia

Overall, 39.0% (n = 23/59) of respondents reported
that their first fracture occurred from age 0 to less
than 10 years, while none of the respondents reported
that their first fracture occurred from age 10 to less
than 18 years. The remaining participants (61%, n =
36/59) either did not respond to this question in the
survey or had not experienced any fractures by the
time of their participation in the study. A total of
13.3% (n = 2/15) of patients reported experiencing
their first fracture from age 0 to less than 1 year (captured in the HOST only).

Surgeries

Patients’ histories of HPP-related surgeries were
assessed in the HIPS (Table 4). More than one-third
(36.4%) of respondents reported one or more HPP-related surgeries, with surgery on the skull (20.5%) being the most frequently reported. Of those patients
who participated in the HOST, 35.7% (n = 5/14) reported having undergone surgery involving internal
surgical instrumentation (screws, rods, plates, or any
internal fixation).

Table 4 History of surgeries in pediatric patients with HPP
Type of surgery

Patients, n (%) (n = 44)

Any surgery

16 (36.4)

Surgery on the skull

9 (20.5)

Osteotomy

5 (11.4)

Root canal

4 (9.1)

Club foot surgery

3 (6.8)

Stapling of growth plates

2 (4.5)

Fracture fixation

2 (4.5)

Bone biopsy

1 (2.3)

The types of surgery presented were assessed by HIPS only
HIPS Hypophosphatasia Impact Patient Survey, HPP hypophosphatasia

A total of 50.8% (n = 30/59) of the respondents reported
using an assistive device and/or braces for mobility at
some time. The mean (SD; range) number of assistive
devices used per patient was 1.2 (1.2; 0–11). At the time
of the survey, the most frequently reported assistive
devices in use were wheelchairs (33.9% of patients) and
in-shoe orthotics (27.1%), while a smaller number reported use of a walker (18.6%) (Fig. 2). Of the respondents participating in the HIPS, 17.1% reported that
home modifications had been made as a consequence of
their HPP. These modifications consisted of alterations
to the kitchen, bathroom, bedroom, and/or entryways.
The HOST assessed worsening or improvement in
patients’ ability to walk. Overall, 40.0% of respondents
(n = 6/15) reported that their ability to walk had worsened since the time of their diagnosis of HPP, while
33.3% (n = 5/15) reported an improvement.

Activities of daily living

Most respondents reported that their health impaired
their physical and mental function, as measured by the
SF-10, which was administered as part of the HIPS
(Fig. 3a). Mean (95% CI) PCS and MCS scores for
pediatric patients with HPP were 23.7 (17.2, 30.3) and
45.6 (41.9, 49.3), respectively, both of which are lower
than the general child population mean of 50 (SD: 10)
[20]. In addition, between 33.4 and 79.5% of the HIPS
respondents reported that they were limited in their ability to undertake moderate activities (such as standing
from a sitting position and walking), bending, lifting, and
daily activities (such as attending school) as a consequence of their physical and/or emotional challenges
(Fig. 3b).

Burden of disease: longitudinal evaluation

The HOST assessed whether respondents’ first HPP
signs/symptoms had improved, worsened, or remained
the same from the time of their first occurrence to the
time of the survey. Overall, 7 respondents reported improvements in one or more of their initial signs/symptoms, while 3 reported worsening and 4 reported no
change in their first signs/symptoms.
In addition, respondents who completed the HOST
were asked whether their additional HPP signs/symptoms had improved, worsened, or remained the same
compared with their severity 5 years prior to the survey.
Improvements in one or more additional signs/symptoms were reported by 4 patients, worsening was reported by 10 patients, and 5 patients reported no change
in one or more additional signs/symptoms (Fig. 4).
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Fig. 2 Proportion of pediatric patients with HPP using assistive devices for disability. Note that patients could report the use of more than one
type of assistive device. Data presented were assessed by both HIPS and HOST unless otherwise stated (n = 59). aHome modifications consisted of
alterations to the kitchen, bathroom, bedroom, and/or entryways. These were assessed by HIPS only (n = 44). There were five respondents who
did not respond to this question in the survey. HIPS, Hypophosphatasia Impact Patient Survey; HOST, Hypophosphatasia Outcomes Study
Telephone interview; HPP, hypophosphatasia

a

b

Fig. 3 Impact of HPP on a) HRQoL and b) activities of daily living
among pediatric patients. a Physical Component Summary and
Mental Component Summary scores as assessed by the SF-10 (HIPS,
n = 44). Mean (SD) scores are given above each bar. b Self-reported
(or caregiver/family member-reported) inability to perform activities
of daily living (HIPS, n = 44). Information in brackets is the reason
given for the specific inability. There were five patients (or
caregivers/family members) who did not respond to this part of the
HIPS. HIPS, Hypophosphatasia Impact Patient Survey; HPP,
hypophosphatasia; HRQoL, health-related quality of life; SD, standard
deviation; SF-10, 10-item Short-Form Health Survey for Children

Discussion
This study characterizes the impact of HPP on the
HRQoL of pediatric patients with HPP as reported by
the patients themselves or their caregivers. The findings
of this study suggest that pediatric patients experience a
high burden of disease and reduced HRQoL, and that
burden of disease may increase and HRQoL reduce further over time as signs/symptoms that impact HRQoL
worsen or new signs/symptoms manifest. Two-thirds of
the patients reported that at least one of their HPP-related additional signs/symptoms had worsened over a 5year period. Overall, the majority of pediatric patients
with HPP reported that the disease often limited their
ability to perform activities of daily living. Most patients
identified physical reasons for these limitations, while
33.4% of patients surveyed stated that emotional
problems were impeding their ability to perform daily
activities. As such, this study highlights the substantial
morbidity that children with HPP frequently experience,
and that many patients experience worsening of their
disease over time.
The findings of this pediatric analysis are broadly
consistent with those reported previously in the analysis
of 125 adults with HPP, which showed that HPP can
confer a high burden of disease in adulthood [7]. Using
the 12-item Short-Form Health Survey version 2, that
analysis indicated that HPP has a wide-ranging and
substantial impact on the HRQoL of adult patients, and
that these patients often experience pain (95% of survey
respondents), fractures (86%), multiple fractures (74%),
muscle weakness (62%), and abnormal gait (52%). A high
percentage (60%) of the patients surveyed also reported
using assistive devices for mobility [7]. Similarly, in this
analysis of pediatric patients, the most commonly reported
signs/symptoms were pain, muscle weakness, and challenges with mobility. However, the reported frequency of
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Fig. 4 Proportion of pediatric patients with HPP experiencing an improvement, worsening, or no change in signs/symptoms compared with 5
years ago. This was assessed by HOST only (n = 15). Patients’ first HPP-related signs/symptoms were excluded from this analysis; respondents
could report up to three signs/symptoms that manifested after their first HPP signs/symptoms. Other HPP signs/symptoms included recurrent
respiratory tract infections, nephrocalcinosis, lack of appetite, difficulty in gaining weight, tight hamstrings/calves, short stature, growth disorders,
low red blood cell count, and other dental/oral problems (abocclusion, malposition of teeth, dysfunction of the tongue). Data for any sign/
symptom are the numbers of patients who reported an improvement, worsening, or no change in their additional signs/symptoms compared
with 5 years prior to their participation in the survey in response to the free-text survey question “What additional symptoms related to HPP do
you have today?”. aOne respondent did not indicate whether their signs/symptoms had improved or worsened, or were unchanged compared
with 5 years ago. bTwo respondents did not indicate whether their signs/symptoms had improved, worsened, or were unchanged compared
with 5 years ago. HOST, Hypophosphatasia Outcomes Study Telephone interview; HPP, hypophosphatasia

occurrence of several HPP-related manifestations differed
substantially between the two patient populations. For example, difficulty gaining weight, delayed walking, and skeletal abnormalities were reported more frequently by
pediatric patients with HPP than by adult patients with
HPP. Some of these differences may be attributed to
growth during childhood, meaning some developmental
and skeletal abnormalities are more likely to occur in
children than in adults.
Notably, fractures occurred less frequently in pediatric
patients than in adults with HPP (36% versus 86%, respectively) and none of the pediatric survey respondents
reported fracture to be a first HPP sign/symptom. The
prevalence of more than one fracture among children
with HPP (15%) was similar to the prevalence in healthy
children, which data indicate is 15–20% [21]. In general,
the occurrence of two or more long bone fractures in
those under 10 years of age, or three or more long bone
fractures in those from age 10 to less than 16 years, or
the occurrence of a vertebral compression fracture is
considered abnormal [21]. While detailed information
about the mechanism of fracture or fracture location
was not collected as part of this study, it is remarkable
that 10.2% of patients have experienced 2–5 fractures,
and 5.1% of patients reported 6–10 fractures. The report
of pseudofractures and non-healing fractures is also noteworthy, as they are reflective of underlying HPP-related
rickets or osteomalacia [4, 18]. Pseudofractures are considered to be a type of insufficiency fracture that can occur
in several forms of rickets and osteomalacia, both genetic
(e.g. HPP and X-linked hypophosphatemia) and acquired

(e.g. severe vitamin D deficiency), [22] and therefore the
occurrence of such fractures is not expected among the
general pediatric population. Non-healing fractures occur
in the general pediatric population in the absence of specific risk factors at a rate of approximately 0.002% per
fracture [23].
Consistent with the previous study among adults with
HPP, the respondents in the current survey scored below
the general child population norm in both the physical
and mental components of the SF-10. Although the
mean MCS scores for pediatric and adult patients reported by the two studies were comparable (45.6 versus
46.4, respectively), the mean PCS score was substantially
lower among pediatric patients with HPP than among
the adult patients who were surveyed (23.7 versus 32.8,
respectively), and the general population (50.0). The high
patient-reported physical burden of HPP is reflected in
the prevalent use of assistive devices, including wheelchairs and in-shoe orthotics, by the adults and children
surveyed in both analyses [7]. While overall levels of use
of assistive devices were similar in adults and pediatric
patients, the types of devices used differed between the
two study groups. For example, only 3% of children reported using crutches compared with 30% of adults [7].
Although studies looking at the burden of disease from
the patient perspective offer important insights into how
patients themselves perceive their HRQoL, the data collected from such studies have several notable limitations.
In this study, HPP diagnosis was not confirmed by a
third party or by examination of patients’ medical records, and the criteria by which a diagnosis of HPP was
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made were not defined. Also, the study population may
not be fully representative of the overall population of
individuals with HPP because patients were invited to
participate in the research through their association with
patient advocacy groups or a referral by their clinician.
Therefore, an element of self-selection was permitted by
the study design, which may have biased the study population towards one with a disproportionate number of
highly motivated patients/caregivers. In addition, the
findings from this study are based on a relatively small
cohort of patients but, considering the rarity of HPP,
may be considered adequate for drawing conclusions
based on the analyses conducted. Recall bias is an inherent limitation of patient-reported data. This study required respondents to state how their reported first
signs/symptoms of HPP changed from the time of their
first occurrence to the time of the survey, and to state
how their reported additional HPP signs/symptoms had
changed compared with 5 years before participating in
the survey. These long recall periods may have reduced
the accuracy of these patient-reported data.

Conclusions
To the best of our knowledge, this is the first study to
characterize the patient-reported burden of disease
among children with HPP. This study highlights that
HPP is associated with a high disease burden and can
significantly affect patients’ HRQoL. Although some
patients can experience improvement of some signs or
symptoms, two-thirds experienced worsening of at least
one of their HPP-related signs/symptoms over time.
Future analyses of data collected by the HPP registry
established in 2015 should extend our current understanding of the natural history, clinical course, and
burden of disease in children and adults with HPP.
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